Appen (APX) reported FY21 results today that were a miss to expectations while they also removed FY22 guidance, instead putting in longer dated revenue guidance. We are cutting our small 3% position.
MM are selling APX in the Flagship Growth Portfolio, taking a loss around $6.30
Add To Hit List
We are increasing our existing position in Xero (XRO) by a further 2% into current weakness, taking it to a 7% portfolio weighting.
MM are increasing XRO in the Flagship Growth Portfolio, allocating a further 2% around $93.00
Add To Hit List
